A Phase 3 interventional study of Amlodipine and Amlodipine in Hypertension, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 15 sites in Japan. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2021-02-11.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.
Among the 187 studies testing amlodipine in Hypertension, this one is the 68th largest by enrollment of the 186 interventional ones that give a count, is one of 17 that started in 2007, is one of 69 in phase 3, and was the 36th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Hyundai Pharm · Sites in Korea, Republic of
Ages 19+
Zentiva, k.s.
Ages 50–79 · Women only
By country, each count listing its studies:
Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 20 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 9 · Phase 3 71 · Phase 4 80
First in 1999; this study’s year is marked. 17 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 305 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 180 across the 186 interventional studies. Of the 156 that completed or were terminated, 53 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 187 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
34 studies in Hypertension by Viatris Inc.: none open now, none under way, none of them phase 3. Of 34 finished, 11 (32%) have results posted.
Among the 34 studies in Hypertension by Viatris Inc., this one is the 16th largest by enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2007, is one of 13 in phase 3, and was the 23rd registered.
Viatris Inc.’s Hypertension studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 187 studies testing amlodipine in Hypertension, from their registry updates:
Among Viatris Inc.’s 34 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The changes in the trough systolic blood pressure from the baseline were assessed after 8 weeks of double-blind treatment with amlodipine 10 mg or amlodipine 5 mg
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Amlodipine
Drug: Amlodipine
Amlodipine 5mg/ day
Amlodipine 10mg/ day
Change in Systolic Blood Pressure (SBP) From Baseline to Week 8
Mean change in the trough SBP
Time frame: Baseline to Week 8
Change in Diastolic Blood Pressure (DBP) From Baseline to Week 8
Mean change in the trough DBP
Time frame: Baseline to Week 8
Combined Mean Change in SBP From Baseline to Week 6 and Week 8 (Mean by Patient)
Arithmetic mean of Week 6 \& Week 8 by patient for "Change from baseline in SBP at Week 6" and "Change from baseline in SBP at Week 8"
Time frame: Baseline to Week 6 and Week 8
Combined Mean Change in DBP From Baseline to Week 6 and Week 8 (Mean by Patient)
Arithmetic mean of Week 6 \& Week 8 by patient for "Change from baseline in DBP at Week 6" and "Change from baseline in DBP at Week 8"
Time frame: Baseline to Week 6 and Week 8
Number of Subjects Achieving the Target Blood Pressure Reduction Value at Week 8
Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \>=65 years old
Time frame: Week 8
Combined Number of Subjects Achieving the Target Blood Pressure Reduction Value at Both Weeks 6 and 8
Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \>=65 years old
Time frame: Week 6 and Week 8
Number of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by >= 10 mmHg at Week 8
Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \>=65 years old
Time frame: Week 8
Combined Number of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by >= 10 mmHg at Both Weeks 6 and 8
Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \>=65 years old
Time frame: Week 6 and Week 8
Trough Plasma Concentrations of Amlodipine -Amlodipine 5 mg
Time frame: Baseline, Week 4 and Week 8
Trough Plasma Concentrations of Amlodipine -Amlodipine 10 mg
Time frame: Baseline, Week 4, and Week 8
Twenty-four (24) centers in Japan
| Milestone | Amlodipine 5 mg | Amlodipine 10 mg |
|---|---|---|
| Started | 154 | 151 |
| Completed | 149 | 146 |
| Not completed | 5 | 5 |
| Withdrew: Adverse event | 3 | 4 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 |
Mean change in the trough SBP
| mmHg | Amlodipine 5 mg | Amlodipine 10 mg |
|---|---|---|
| Change in Systolic Blood Pressure (SBP) From Baseline to Week 8 | -7.0 (-8.8 to -5.2) | -13.7 (-15.4 to -12.0) |
Mean change in the trough DBP
| mmHg | Amlodipine 5 mg | Amlodipine 10 mg |
|---|---|---|
| Change in Diastolic Blood Pressure (DBP) From Baseline to Week 8 | -2.7 (-3.9 to -1.4) | -6.8 (-8.0 to -5.5) |
Arithmetic mean of Week 6 \& Week 8 by patient for "Change from baseline in SBP at Week 6" and "Change from baseline in SBP at Week 8"
| mmHg | Amlodipine 5 mg | Amlodipine 10 mg |
|---|---|---|
| Combined Mean Change in SBP From Baseline to Week 6 and Week 8 (Mean by Patient) | -6.8 (-8.4 to -5.2) | -13.9 (-15.5 to -12.4) |
Arithmetic mean of Week 6 \& Week 8 by patient for "Change from baseline in DBP at Week 6" and "Change from baseline in DBP at Week 8"
| mmHg | Amlodipine 5 mg | Amlodipine 10 mg |
|---|---|---|
| Combined Mean Change in DBP From Baseline to Week 6 and Week 8 (Mean by Patient) | -2.5 (-3.6 to -1.4) | -6.5 (-7.6 to -5.5) |
Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \>=65 years old
| participants | Amlodipine 5 mg | Amlodipine 10 mg |
|---|---|---|
| Number of Subjects Achieving the Target Blood Pressure Reduction Value at Week 8 | 43 | 66 |
Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \>=65 years old
| participants | Amlodipine 5 mg | Amlodipine 10 mg |
|---|---|---|
| Combined Number of Subjects Achieving the Target Blood Pressure Reduction Value at Both Weeks 6 and 8 | 22 | 52 |
Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \>=65 years old
| participants | Amlodipine 5 mg | Amlodipine 10 mg |
|---|---|---|
| Number of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by >= 10 mmHg at Week 8 | 35 | 61 |
Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \>=65 years old
| participants | Amlodipine 5 mg | Amlodipine 10 mg |
|---|---|---|
| Combined Number of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by >= 10 mmHg at Both Weeks 6 and 8 | 16 | 44 |
| ng/mL | Baseline | Week 4 | Week 8 |
|---|---|---|---|
| Trough Plasma Concentrations of Amlodipine -Amlodipine 5 mg | 7.02 (6.5 to 7.5) | 6.83 (6.3 to 7.4) | 7.03 (6.6 to 7.5) |
| ng/mL | Baseline | Week 4 | Week 8 |
|---|---|---|---|
| Trough Plasma Concentrations of Amlodipine -Amlodipine 10 mg | 7.18 (6.7 to 7.7) | 16.9 (15.7 to 18.1) | 16.9 (15.7 to 18.2) |
| Age, Customized(partcipants) | Amlodipine 5 mg | Amlodipine 10 mg | Total |
|---|---|---|---|
| < 20 years | 0 | 0 | 0 |
| 20 to 44 years | 15 | 15 | 30 |
| 45 to 64 years | 75 | 70 | 145 |
| >= 65 years | 64 | 66 | 130 |
| Sex: Female, Male(Participants) | Amlodipine 5 mg | Amlodipine 10 mg | Total |
|---|---|---|---|
| Female | 70 | 59 | 129 |
| Male | 84 | 92 | 176 |
| Region of Enrollment(participants) | Amlodipine 5 mg | Amlodipine 10 mg | Total |
|---|---|---|---|
| Japan | 154 | 151 | 305 |
The record gives a start of Jan 2007, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2008, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amlodipine
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →